Search research articles
Contact Us
Filters
Showing results (1-10 of 29) with videos related to
Page
of 3
Sort By:
Immunology Letters
|
July 19, 2008
Characterization of oligomers induced by inverse agonists of CTLA-4
Wendy A Teft, Joaquín Madrenas
Current Opinion in Investigational Drugs (London, England : 2000)
|
November 23, 2006
The immunological synapse as a novel therapeutic target
Wendy A Teft, Joaquin Madrenas
Journal of Immunology (Baltimore, Md. : 1950)
|
September 6, 2007
Molecular determinants of inverse agonist activity of biologicals targeting CTLA-4
Wendy A Teft, Joaquín Madrenas
Pharmacogenomics
|
October 4, 2013
Sunny outlook for personalized medicine: tamoxifen and beyond
Wendy A Teft, Richard B Kim
BMC Immunology
|
May 2, 2009
Structure-Function analysis of the CTLA-4 interaction with PP2A
Wendy A Teft, Thu A Chau, Joaquín Madrenas
Annual Review of Immunology
|
March 23, 2006
A molecular perspective of CTLA-4 function
Wendy A Teft, Mark G Kirchhof, Joaquín Madrenas
Genome
|
August 12, 2005
Tarsus determination in Drosophila melanogaster
Anthony Percival-Smith, Wendy A Teft, Jodi Lynn Barta
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
December 15, 2010
Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1)
Wendy A Teft, Sara E Mansell, Richard B Kim
BMC Cancer
|
May 13, 2016
Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFα biologic for ulcerative colitis: a case report
Sara L Henderson, Wendy A Teft, Richard B Kim
Pharmacogenetics and Genomics
|
June 11, 2014
Profound reduction in the tamoxifen active metabolite endoxifen in a patient on phenytoin for epilepsy compared with a CYP2D6 genotype matched cohort
Steven E Gryn, Wendy A Teft, Richard B Kim
Page
of 3
Search research articles
Search
Showing results (1-10 of 29) with videos related to
Sort By:
Page
of 3
Immunology Letters
|
July 19, 2008
Characterization of oligomers induced by inverse agonists of CTLA-4
Wendy A Teft, Joaquín Madrenas
Current Opinion in Investigational Drugs (London, England : 2000)
|
November 23, 2006
The immunological synapse as a novel therapeutic target
Wendy A Teft, Joaquin Madrenas
Journal of Immunology (Baltimore, Md. : 1950)
|
September 6, 2007
Molecular determinants of inverse agonist activity of biologicals targeting CTLA-4
Wendy A Teft, Joaquín Madrenas
Pharmacogenomics
|
October 4, 2013
Sunny outlook for personalized medicine: tamoxifen and beyond
Wendy A Teft, Richard B Kim
BMC Immunology
|
May 2, 2009
Structure-Function analysis of the CTLA-4 interaction with PP2A
Wendy A Teft, Thu A Chau, Joaquín Madrenas
Annual Review of Immunology
|
March 23, 2006
A molecular perspective of CTLA-4 function
Wendy A Teft, Mark G Kirchhof, Joaquín Madrenas
Genome
|
August 12, 2005
Tarsus determination in Drosophila melanogaster
Anthony Percival-Smith, Wendy A Teft, Jodi Lynn Barta
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
December 15, 2010
Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1)
Wendy A Teft, Sara E Mansell, Richard B Kim
BMC Cancer
|
May 13, 2016
Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFα biologic for ulcerative colitis: a case report
Sara L Henderson, Wendy A Teft, Richard B Kim
Pharmacogenetics and Genomics
|
June 11, 2014
Profound reduction in the tamoxifen active metabolite endoxifen in a patient on phenytoin for epilepsy compared with a CYP2D6 genotype matched cohort
Steven E Gryn, Wendy A Teft, Richard B Kim
Page
of 3